In the OASIS Phase IIIa study, oral semaglutide 50 mg once daily helped overweight or obese adults lose 15.1% of their body weight, or 17.4% if they adhered to treatment, reports Novo Nordisk. The 7 mg and 14 mg oral semaglutide variants are currently approved for type 2 diabetes under the name Rybelsus.
In line with previous studies, the Bavarian study found that a COVID-19 diagnosis was associated with an increased incidence of type 1 diabetes in children. (American Medical Association)
The United States Preventive Services Task Force (USPSTF) is currently seeking public opinion on its draft plan for research into weight loss interventions to prevent obesity-related morbidity and mortality in adults.
Compared with women without diabetes, middle-aged women with prediabetes (fasting blood sugar levels between 100 and 125 mg/dL) were 120% more likely to have fractures during and after the menopausal transition. (JAMA network open)
Valbiotis announced that Totum 63, a research-based combination of five plant extracts, significantly reduced fasting blood glucose levels in patients with pre-diabetes and early untreated type 2 diabetes in the Phase II/III REVERSE-IT study.
The weight-loss drug semaglutide (Wegovy) may reduce the risk of heart disease, according to early trial results. (Reuters)
Kristen Monaco is a staff writer specializing in endocrinology, psychiatry and nephrology news. She has been based in the New York office since 2015.
The materials on this website are for informational purposes only and are not a substitute for medical advice, diagnosis, or treatment from a qualified health care provider. © 2005–2022 MedPage Today, LLC, a Ziff Davis company. All rights reserved. Medpage Today is one of the federally registered trademarks of MedPage Today, LLC and may not be used by third parties without express permission.
Post time: Jun-15-2023